Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.

Diao W, Cai H, Chen L, Jin X, Liao X, Jia Z.

Curr Top Med Chem. 2019;19(1):33-56. doi: 10.2174/1568026619666190201100739. Review.

PMID:
30706785
2.

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.

Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL.

Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004. Review.

PMID:
27553466
3.

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.

Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL.

J Nucl Med. 2017 Sep;58(Suppl 2):67S-76S. doi: 10.2967/jnumed.116.186767. Review.

4.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Epub 2016 May 3. Review.

5.

PSMA PET and Radionuclide Therapy in Prostate Cancer.

Bouchelouche K, Turkbey B, Choyke PL.

Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3. Review.

6.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
7.

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.

Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, Bockisch A, Gotthardt M, Rijpkema M, Boerman OC.

Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection 2015. Review.

8.

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J.

J Med Radiat Sci. 2017 Mar;64(1):52-60. doi: 10.1002/jmrs.227. Review.

9.

New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy.

Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M.

Clin Cancer Res. 2016 Jan 1;22(1):9-15. doi: 10.1158/1078-0432.CCR-15-0820. Review.

10.

Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.

Barrio M, Fendler WP, Czernin J, Herrmann K.

Expert Rev Mol Diagn. 2016 Nov;16(11):1177-1188. Epub 2016 Oct 14. Review.

PMID:
27679869
11.

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U.

J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.

12.

[PSMA-targeted radioligand therapy in prostate cancer].

Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M.

Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3. Review. German.

PMID:
27885457
13.

Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.

Pillai MRA, Nanabala R, Joy A, Sasikumar A, Russ Knapp FF.

Nucl Med Biol. 2016 Nov;43(11):692-720. doi: 10.1016/j.nucmedbio.2016.08.006. Epub 2016 Aug 11. Review.

PMID:
27589333
14.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S.

Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.

PMID:
29752180
15.

Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.

Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C Jr, Zheng X, Bi C, Hu B, Warren JD, Hage DS, DiMagno SG, Babich JW.

J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967/jnumed.116.188722. Epub 2017 Apr 27.

16.

Prostate-specific membrane antigen radioligand therapy of prostate cancer.

Beheshti M, Heinzel A, von Mallek D, Filss C, Mottaghy FM.

Q J Nucl Med Mol Imaging. 2019 Mar;63(1):29-36. doi: 10.23736/S1824-4785.19.03155-8. Epub 2019 Jan 15. Review.

17.

Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.

Benešová M, Umbricht CA, Schibli R, Müller C.

Mol Pharm. 2018 Mar 5;15(3):934-946. doi: 10.1021/acs.molpharmaceut.7b00877. Epub 2018 Feb 5.

PMID:
29400475
18.

177Lu-PSMA Radioligand Therapy for Prostate Cancer.

Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M.

J Nucl Med. 2017 Aug;58(8):1196-1200. doi: 10.2967/jnumed.117.191023. Epub 2017 Jun 29. Review. Erratum in: J Nucl Med. 2018 Feb;59(2):346.

19.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Mease RC, Foss CA, Pomper MG.

Curr Top Med Chem. 2013;13(8):951-62. Review.

20.

Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.

Ceci F, Castellucci P, Fanti S.

Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub 2018 Mar 8. Review.

Supplemental Content

Support Center